Which company develops and produces Tepotinib (Tuodekang) and its background introduction

Tepotinib is a targeted anti-cancer drug developed and produced by the German pharmaceutical giant Merck KGaA, Darmstadt, Germany. The drug is mainly targeted at specific groups of patients with non-small cell lung cancer (NSCLC) who have METexon14 skipping mutations (METex14). During the research and development process of tepotinib, Merck Group invested a lot of clinical research resources, and it has been approved for marketing in the United States, Japan and some European countries. Its launch has filled the gap in the field of targeted treatment for METex14 mutated lung cancer, giving new hope to this group of patients who originally lacked effective treatment options.

The research and development background of Tepotinib stems from in-depth research on the MET signaling pathway. METAbnormal activation of the gene has been confirmed to play a key role in the development of various tumors, and METex14 skipping mutations can lead to the continued growth and survival of cancer cells. Relying on its long-term accumulation in the field of molecular targeted therapy, Merck has successfully designed a highly selective, small molecule oral MET inhibitor - Tepotinib, which can effectively block abnormally activated MET signals, thereby inhibiting tumor progression. This research and development direction is of great significance under the global trend of precision tumor treatment.

The pivotal study of tepotinib during clinical development was the VISION trial, a multicenter, open-label, international clinical trial. Trial results show that tepotinib exhibits a high objective response rate (ORR) and durable response time (DOR) in patients with METex14 mutated non-small cell lung cancer, and its safety is controllable. This achievement not only promoted its accelerated approval in various countries, but also made it one of the first oral targeted drugs approved for METex14 mutations, and also provided clinical experience reference for the development of other similar drugs.

Merck’s market strategy after the launch of tepotinib is also quite forward-looking. In addition to its presence in major markets in Europe, America and Asia, it is also cooperating with medical institutions in many countries to promote the popularization of MET mutation testing in clinical practice so that more patients can accurately match medications. In addition, Merck is continuing to evaluate tepotinib in other METMETDrive the application potential in tumors (such as gastric cancer, liver cancer, etc.), with the intention of making it a precise treatment solution for multiple tumor indications. With its clear molecular target, significant clinical efficacy and expanding indications, tepotinib has become one of the important representatives in the field of MET inhibitors.

Reference materials:https://www.drugs.com/